Treatment of recurrent herpes simplex labialis with levamisole.

Antimicrobial Agents and Chemotherapy
S L SpruanceM R Klauber

Abstract

Because deficient immune responses may play a contributory role in recurrent herpes simplex labialis, an immunomodulating agent, levamisole, has been advocated for therapy. Forty-two patients with a high frequency of recurrent herpes simplex labialis were followed for a mean of 7.8 months (range 4 to 12) and treated for 3 days at the onset of each episode of herpes with one of three different doses of levamisole or placebo in a randomized, double-blind study. Statistical analysis revealed that as the dosage increased, so did the frequency of recurrences (P = 0.007). Conversely, duration of the lesions and lesion pain decreased with increasing dosage (P = 0.05 and 0.03). These results indicate that levamisole is not an appropriate drug for the management of recurrent herpes simplex labialis. The paradoxical response to an immunomodulator (increased frequency, decreased severity) provides evidence that altered host responses may contribute to the pathogenesis of the disease.

References

Oct 8, 1977·Lancet·K A Mehr, L Albano
Jun 16, 1977·The New England Journal of Medicine·K H RandT C Merigan
Jul 14, 1977·The New England Journal of Medicine·S L SpruanceW Miller
May 1, 1978·The Journal of Infectious Diseases·A S RussellM Grace
Jan 1, 1972·The American Journal of Medicine·S A MullerR K Winkelmann
Dec 7, 1974·British Medical Journal·J Symoens, J Brugmans

❮ Previous
Next ❯

Citations

Apr 24, 1980·The New England Journal of Medicine·M S Hirsch, M N Swartz
Mar 24, 2007·Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics·Sook-Bin Woo, Stephen J Challacombe
Apr 1, 1979·The British Journal of Venereal Diseases·J Söltz-Szöts, D Fanta
Apr 17, 2015·The Cochrane Database of Systematic Reviews·Kirk R Wilhelmus

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Related Papers

Archives of Dermatology
J K Robinson, S K Spencer
The Journal of Asthma Research
P Lynne-DaviesB J Sproule
Journal of Consulting and Clinical Psychology
D J Stewart, M L Patterson
© 2021 Meta ULC. All rights reserved